. A lipophilic derivative of MDP, muramyl tripeptide phosphoethanolamine (MTP-PE), is more efficiently incorporated into liposomes and is approximately 2.5 times as potent as the parent molecule in generating tumouricidal activity in macrophages (Sone et al., 1986) . Systemic administration of liposome encapsulated MTP-PE leads to activation of macrophages in visceral tissues such as the liver and lung (Xu & Fidler 1984) . This has been related to the ability of MTP-PE to reduce tumour burden at these sites in syngeneic murine tumour models (Fidler et al., 1981; Phillips et al., 1985; Talmadge et al., 1986) . As cells of the monocyte-macrophage lineage constitute a major population of cells in the peritoneal cavity, we speculated that injection of liposome-encapsulated MTP-PE into this site would be an efficient way to activate these cells to kill tumours in the vicinity. Human ovarian cancer characteristically spreads within the confines of the peritoneal cavity, and therefore represents a relevant tumour for treatment by intraperitoneally administered antitumour therapies.
In this paper we describe the results of treating intraperitoneal human ovarian cancer xenografts in nude mice with intraperitoneal administrations of liposome encapsulated MTP-PE. In addition, the effect of simultaneous administrations of recombinant murine granulocytemacrophage colony stimulating factor (muGM-CSF) was studied. Intraperitoneal administration of muGM-CSF has been shown to increase the number of peritoneal macrophages (Metcalf et al., 1987) , and enhance macrophage phagocytosis and tumour killing (Grabstein et al., 1986; Metcalf et al., 1987) .
The results suggest that intracavitary therapy with liposome encapsulated MTP-PE may offer a new therapeutic modality for human ovarian cancer, and that the therapeutic effect can be potentiated by recombinant muGM-CSF in these xenograft models.
Methods and materials
Xenografts and mice 6-12 week old specific pathogen free athymic (nu/nu) female mice of mixed genetic background were used. Ovarian cancer xenografts OS, HU, and LA were established from primary human tumours as described previously (Spinmix, Gallenkamp) . This was further diluted in PBS, to give a MTP-PE concentration of 66.7 ig ml-' (20 1tmol ml-'). 0.5 ml (10 tmol MTP-PE) of this was used per i.p. injection. Liposomes of the same lipid constitution containing PBS only were prepared identically. muGM-CSF Recombinant murine GM-CSF (rMu muGM-SCF) was provided by Dr J. Mermod (Glaxo, Geneva, Switzerland). The muGM-CSF was diluted in PBS/BSA (3 mg ml-') to a concentration of 1 yg ml-'. One hundred t1l (100 ng) of this was used per i.p. injection, as this dose has been shown to lead to an increase in the peritoneal cell numbers in mice (Metcalf, CSF was 2.7 x 107 U mg-'. The endotoxin concentration of the muGM-CSF preparation was less than 10 EU mg-' (LAL assay liposomes showed many viable clumps of tumour cells amongst the host peritoneal cells (Figure 2a) . In MTP-PE treated mice however, very few tumour cells were seen, and the tumour cells present were surrounded by clusters of host cells that were morphologically macrophages (Figure 2b (Figure 3 ). Figure 4 (a,b). An addictive effect on the survival duration of mice with the HU xenograft was apparent in this experiment (Figure 4a ), mice receiving combination therapy surviving significantly longer than those treated with MTP-PE or GM-CSF alone (P <.05). Mice treated with rMu GM-CSF alone did not show significantly prolonged survival compared to PBSA treated mice. In the rapidly growing LA41 xenograft, therapy with MTP-PE alone or GM-CSF alone had no effect. Combination therapy led to significantly improved survival (P <.01) suggesting a synergistic effect (Figure 4b ). Days after tumour injection Figure 4 The effect of combining therapy with GM-CSF and MTP-PE lipsomes in the a HU xenograft and b, the LA xenograft.
marked differences in the sensitivity to treatment between different xenografts. Thus 80% of mice with the OS xenograft were cured, whereas only a doubling of survival time was seen in the early passages of the LA xenograft. At a later passage when the LA xenograft was more aggressive, the liposome-encapsulated MTP-PE was ineffective (Figure 4b ).
This variation in susceptibility does not correlate to the susceptibility to tumour necrosis factor (TNF). We have shown that the OX xenograft is TNF-resistant, whereas mice bearing the LA (including later passages) and HU tumours show increased survival after injection of TNF intraperitoneally (Malik et al., 1989) . MTP-PE must therefore activate TNF independent tumouricidal mechanisms. Additionally we have been unable to show any biologically active TNF production in the peritoneal lavage fluid from MTP-PE treated mice, using a biological assay with a sensitivity of 1 pg ml-' TNF (Espevik & Niessen-Meyer 1986) . In order to elucidate the possible mechanism of action of MTP-PE in these models, we studied the changes in peritoneal cell populations after intraperitoneal injections. In murine ovarian cancer models in the antitumour effect of Corynebacterium parvum has been linked to the influx of neutrophils (Lichtenstein et al., 1984) , and there is also in vitro evidence that neutrophils can be cytotoxic for ovarian cancer cells (Lichtenstein et al., 1989) . For this reason we studied the extent of neutrophil influx in mice injected intraperitoneally with liposome preparations. Both the placebo and active liposomes led to an influx of neutrophils into the peritoneal cavity in tumour bearing and control mice. However there were no significant differences were noted in either the total number of peritoneal cells or the total number of neutrophils following injection of placebo or active liposomes. The extent of neutrophil infiltration does not account for the difference in therapeutic efficacy of placebo and active liposomes. The mechanisms underlying the increase in peritoneal cell numbers after injection of liposome preparations remain to be elucidated. Recent data have shown that MDP can lead to the induction of GM-CSF and M-CSF in mice (Broudy et al., 1990) , but these cytokines are unlikely to account for the rapid changes in peritoneal cell populations seen in mice injected with liposome preparations (Sayers et al., 1988) .
As intraperitoneal or systemic administration of muramyl dipeptide or its analogues do not increase NK cell activity in the peritoneal cell population in mice (Talmadge 1985) , we have assumed that the therapeutic effects described here are a consequence of the well documented effects of MTP-PE on macrophage function (Sone et al., 1980 (Sone et al., , 1986b . This is also suggested by the clustering of peritoneal macrophages around tumour cells seen after injection of liposome encapsulated MTP-PE in to mice bearing the OS tumour. Cytokines released by these macrophages, for example interleukin-1 may contribute to the antitumour effect of MPT-PE liposomes.
Treatment of tumour bearing mice with recombinant GM-CSF alone did not prolong survival in mice with the LA, HU, or OS xenografts. The addition of GM-CSF to the liposome regime led to a significant additive effect on the survival of mice injected with either the LA or HU xenografts. In the OS xenograft, no additional effect was noted, possibly because of the high cure rate achieved with liposome encapsulated MTP-PE alone. We are unable to determine whether the GM-CSF effect is due to a direct additive effect on the antitumour activity of the resident peritoneal macrophages, or simply based on the generation of increased numbers of tumouricidal macrophages. The tumour xenografts do not grow in vitro, and we are unable to perform in vitro cytotoxicity assays to answer this question.
In conclusion these data show that intraperitoneal therapy with liposome encapsulated MTP-PE can be added to the list of potential 'biological' agents, such as TNF and interferons Manetta et al., 1989) and IL-2 stimulated killer cells (LAK cells) (Ortaldo et al., 1986) , that can be used in the treatment of ovarian cancer. Neither the frequency, nor duration of liposome administration were optimised in the present study, so that the results obtained might still be improved. It is of some interest that liposome encapsulated MTP-PE has also been shown to lead to systemic activation of tumouricidal macrophages following oral administration (Fidler et al., 1987) . We have not however been able to show increased survival in the OS xenograft this using an identical oral dose schedule that was used for intraperitoneal therapy.
